Wnt signaling in Alzheimer's disease: up or down, that is the question

Chemical Compounds

• Antagonist 27%
• Beta-Amyloid 100%
• Disorder 25%
• Drug Target 33%
• Glycogen 70%
• Low-Density Lipoprotein 34%
• Mutation 25%
• Protein 24%

Medicine & Life Sciences

• Alzheimer Disease 69%
• Amyloid 18%
• Amyloid beta-Protein Precursor 11%
• Amyloid Plaques 10%
• Apolipoproteins E 10%
• beta Catenin 40%
• Down-Regulation 6%
• Genes 3%
• Genetic Variation 9%
• Glycogen Synthase Kinase 3 26%
• Low Density Lipoprotein Receptor-Related Protein-6 16%
• Missense Mutation 10%
• Neurodegenerative Diseases 8%
• Pathology 6%
• Pharmaceutical Preparations 4%
• Phosphorylation 6%
• Presenilin-1 13%
• Presenilins 14%
• Therapeutics 1%
• Wnt Signaling Pathway 22%